tiprankstipranks
Advertisement
Advertisement

PRLD Stock Latest News

Prelude Therapeutics Shareholders Back Leadership and Governance
Company AnnouncementsPrelude Therapeutics Shareholders Back Leadership and Governance
1M ago
8K
PRLD
Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
PremiumThe Fly
Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
2M ago
PRLD
Prelude Therapeutics Launches Phase 1 Trial and Extends Runway
PremiumCompany Announcements
Prelude Therapeutics Launches Phase 1 Trial and Extends Runway
2M ago
8K
PRLD
Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)
PremiumThe Fly
Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)
2M ago
PRLD
Prelude Therapeutics initiated with a Buy at D. Boral Capital
PremiumThe Fly
Prelude Therapeutics initiated with a Buy at D. Boral Capital
2M ago
PRLD
Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers
PremiumCompany AnnouncementsPrelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers
2M ago
PRLD
Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright
Premium
The Fly
Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright
3M ago
PRLD
Prelude Therapeutics Prices Public Offering to Extend Runway
Premium
Company Announcements
Prelude Therapeutics Prices Public Offering to Extend Runway
3M ago
8K
PRLD
Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results
PremiumCompany Announcements
Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results
3M ago
8K
PRLD
Prelude Therapeutics presents new preclinical data from PRT13722 study
PremiumThe Fly
Prelude Therapeutics presents new preclinical data from PRT13722 study
3M ago
PRLD
Prelude Therapeutics Appoints Veteran Oncologist as New CMO
PremiumCompany Announcements
Prelude Therapeutics Appoints Veteran Oncologist as New CMO
3M ago
8K
PRLD
Prelude Therapeutics announces Charles Morris as chief medical officer
PremiumThe Fly
Prelude Therapeutics announces Charles Morris as chief medical officer
3M ago
PRLD
Prelude Therapeutics management to meet with Citizens
PremiumThe FlyPrelude Therapeutics management to meet with Citizens
4M ago
PRLD
Prelude Therapeutics Establishes New ATM Equity Offering Facility
Premium
Company Announcements
Prelude Therapeutics Establishes New ATM Equity Offering Facility
4M ago
8K
PRLD
Prelude Therapeutics price target raised to $6 from $3 at Citizens
Premium
The Fly
Prelude Therapeutics price target raised to $6 from $3 at Citizens
4M ago
PRLD
Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
PremiumCompany Announcements
Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
4M ago
8K
PRLD
Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year
PremiumThe Fly
Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year
4M ago
PRLD
Prelude Therapeutics sees cash runway into 2Q27
PremiumThe Fly
Prelude Therapeutics sees cash runway into 2Q27
4M ago
PRLD
Prelude Therapeutics Wins FDA IND Clearance for PRT12396
PremiumCompany Announcements
Prelude Therapeutics Wins FDA IND Clearance for PRT12396
5M ago
8K
PRLD
Prelude receives FDA clearance for investigational IND for PRT12396
PremiumThe FlyPrelude receives FDA clearance for investigational IND for PRT12396
5M ago
PRLD
Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology
Premium
Company Announcements
Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology
6M ago
ONC
PRLD
Prelude Therapeutics unveils strategic investor presentation on pipelines
Premium
Company Announcements
Prelude Therapeutics unveils strategic investor presentation on pipelines
6M ago
8K
PRLD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >